Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-19T23:32:37.744Z Has data issue: false hasContentIssue false
  • English
  • Français

Olanzapine-fluoxetine combination in treatment-resistant depression

Published online by Cambridge University Press:  16 April 2020

S. Dube ,
S. Paul ,
T. Sanger ,
L. Van Campen ,
S. Corya  and
G. Tollefson
S. Dube
Affiliation:
Eli Lilly & Company, Indiana, USA
S. Paul
Affiliation:
Eli Lilly & Company, Indiana, USA
T. Sanger
Affiliation:
Eli Lilly & Company, Indiana, USA
L. Van Campen
Affiliation:
Eli Lilly & Company, Indiana, USA
S. Corya
Affiliation:
Eli Lilly & Company, Indiana, USA
G. Tollefson
Affiliation:
Eli Lilly & Company, Indiana, USA

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Posters, Sunday, 5 May 2002
Information
European Psychiatry , Volume 17 , Issue S1 , May 2002 , pp. 98s
Copyright
Copyright © Elsevier, Paris 2002
Submit a response

Comments

No Comments have been published for this article.